Drug · DIN 02283565
RIVA-RISPERIDONE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 11, 2017; first marketed July 31, 2006.
- Drug Identification Number (DIN)
- 02283565
- Company (DIN owner)
- Laboratoire Riva Inc.Blainville, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Risperidone N05AX08
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RISPERIDONE | 0.25 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 11, 2017: NOC 19523Abbreviated New Drug Submission (ANDS) · Licensing agreement between two companies
- June 26, 2013: NOC 14498Abbreviated New Drug Submission (ANDS) · Administrative licensing agreement between two companies
- July 18, 2006: NOC 8153Abbreviated New Drug Submission (ANDS) · New manufacturer and product name
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “riva-risperidone”. A notice may cover another product or only some lots: read it to see what it covers.
- Recall: One lot of Riva-Risperidone 0.25 mg tablets recalled due to a packaging errorOctober 9, 2021 · Drugs
- Riva-Risperidone (2021-10-07)October 7, 2021 · Drugs · Product safety · Type I
Other DINs named RIVA-RISPERIDONE
- DIN 02283581 · Marketed
- DIN 02283603 · Marketed
- DIN 02283611 · Marketed
- DIN 02283638 · Marketed
- DIN 02283573 · Dormant